Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
Neurotrophic keratitis treatment gains orphan drug designationThe FDA has designated Dompé’s rhNGF (recombinant human nerve growth factor) as an orphan drug for the treatment of neurotrophic keratitis.
Study finds possible new treatment of corneal ulcers in neurotrophic keratitis patientsItalian biopharmaceutical company Dompé is researching recombinant human nerve growth factor (rhNGF) for the treatment of corneal ulcers in patients affected by neurotrophic keratitis.